메뉴 건너뛰기
Antimicrobial Agents and Chemotherapy
Volumn 59, Issue 12, 2015, Pages 7161-7169
Clinically available medicines demonstrating anti-toxoplasma activity
Author keywords

[No Author keywords available]
Indexed keywords

ANTIPARASITIC AGENT; ARPRINOCID; ARTEMISININ; AURANOFIN; AZITHROMYCIN; CLARITHROMYCIN; COTRIMAZINE; CRIZOTINIB; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DECOQUINATE; DICLAZURIL; DIDANOSINE; FLUOROURACIL; FLUPHENAZINE; GEFITINIB; METHOTREXATE; MILTEFOSINE; MONENSIN; NICLOSAMIDE; PONAZURIL; PYRIMETHAMINE SULFADIAZINE; RIFABUTIN; RIFAPENTINE; ROBENIDINE; SALINOMYCIN; TOLTRAZURIL; TRICLOSAN; TROVAFLOXACIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; ATOVAQUONE; CLINDAMYCIN; MACROLIDE; NEUROLEPTIC AGENT; PYRIMETHAMINE; SULFADIAZINE;
EID: 84954497209     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02009-15     Document Type: Review
Times cited : (88)
References (107)
  • 1
    • 57749176642 scopus 로고    scopus 로고
    • The history of Toxoplasma gondii-The first 100 years
    • Dubey JP. 2008. The history of Toxoplasma gondii-the first 100 years. J Eukaryot Microbiol 55: 467-475. http://dx.doi.org/10.1111/j.1550 -7408.2008.00345.x.
    • (2008) J Eukaryot Microbiol , vol.55 , pp. 467-475
    • Dubey, J.P.1
  • 2
    • 84859776735 scopus 로고    scopus 로고
    • Toxoplasma on the brain: Understanding host-pathogen interactions in chronic CNS infection
    • Kamerkar S, Davis PH. 2012. Toxoplasma on the brain: Understanding host-pathogen interactions in chronic CNS infection. J Parasitol Res 2012: 589295. http://dx.doi.org/10.1155/2012/589295.
    • (2012) J Parasitol Res , vol.2012 , pp. 589295
    • Kamerkar, S.1    Davis, P.H.2
  • 3
    • 0035005107 scopus 로고    scopus 로고
    • Decrease of psychomotor performance in subjects with latent "asymptomatic" toxoplasmosis
    • Havlícek J, Gasová ZG, Smith AP, Zvára K, Flegr J. 2001. Decrease of psychomotor performance in subjects with latent "asymptomatic" toxoplasmosis. Parasitology 122: 515-520.
    • (2001) Parasitology , vol.122 , pp. 515-520
    • Havlícek, J.1    Gasová, Z.G.2    Smith, A.P.3    Zvára, K.4    Flegr, J.5
  • 4
    • 0019619013 scopus 로고
    • Behavioral alterations caused by parasitic infection in case of latent toxoplasma infection
    • Piekarski G. 1981. Behavioral alterations caused by parasitic infection in case of latent toxoplasma infection. Zentralbl Bakteriol Mikrobiol Hyg A 250: 403-406.
    • (1981) Zentralbl Bakteriol Mikrobiol Hyg A , vol.250 , pp. 403-406
    • Piekarski, G.1
  • 5
    • 84875488509 scopus 로고    scopus 로고
    • How and why Toxoplasma makes us crazy
    • Flegr J. 2013. How and why Toxoplasma makes us crazy. Trends Parasitol 29: 156-163. http://dx.doi.org/10.1016/j.pt.2013.01.007 .
    • (2013) Trends Parasitol , vol.29 , pp. 156-163
    • Flegr, J.1
  • 6
    • 0033647231 scopus 로고    scopus 로고
    • Toxoplasma gondii: From animals to humans
    • Tenter AM, Heckeroth AR, Weiss LM. 2000. Toxoplasma gondii: From animals to humans. Int J Parasitol 30: 1217-1258. http://dx.doi.org/10 .1016/S0020-7519(00)00124-7.
    • (2000) Int J Parasitol , vol.30 , pp. 1217-1258
    • Tenter, A.M.1    Heckeroth, A.R.2    Weiss, L.M.3
  • 10
    • 0030739030 scopus 로고    scopus 로고
    • Economic costs and trade impacts of microbial foodborne illness
    • Buzby JC, Roberts T. 1997. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 50: 57-66.
    • (1997) World Health Stat Q , vol.50 , pp. 57-66
    • Buzby, J.C.1    Roberts, T.2
  • 11
    • 33947576645 scopus 로고    scopus 로고
    • Adenosine metabolism in Toxoplasma gondii: Potential targets for chemotherapy
    • el Kouni MH. 2007. Adenosine metabolism in Toxoplasma gondii: Potential targets for chemotherapy. Curr Pharm Des 13: 581-597. http://dx .doi.org/10.2174/138161207780162836.
    • (2007) Curr Pharm Des , vol.13 , pp. 581-597
    • El Kouni, M.H.1
  • 12
    • 0030497769 scopus 로고    scopus 로고
    • Treatment regimens for patients with toxoplasmic encephalitis
    • discussion 1036
    • Fung HB, Kirschenbaum HL. 1996. Treatment regimens for patients with toxoplasmic encephalitis. Clin Ther 18: 1037-1056; discussion 1036. http://dx.doi.org/10.1016/S0149-2918(96)80059-2.
    • (1996) Clin Ther , vol.18 , pp. 1037-1056
    • Fung, H.B.1    Kirschenbaum, H.L.2
  • 16
    • 0021246884 scopus 로고
    • New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: Comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A
    • Mack DG, McLeod R. 1984. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: Comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother 26: 26-30. http://dx.doi.org/10.1128/AAC.26.1.26.
    • (1984) Antimicrob Agents Chemother , vol.26 , pp. 26-30
    • Mack, D.G.1    McLeod, R.2
  • 17
    • 0025150040 scopus 로고
    • In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice
    • Piketty C, Derouin F, Rouveix B, Pocidalo JJ. 1990. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother 34: 1467-1472. http://dx.doi.org/10.1128/AAC.34.8 .1467.
    • (1990) Antimicrob Agents Chemother , vol.34 , pp. 1467-1472
    • Piketty, C.1    Derouin, F.2    Rouveix, B.3    Pocidalo, J.J.4
  • 18
    • 0028109541 scopus 로고
    • Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine
    • Alder J, Hutch T, Meulbroek JA, Clement JC. 1994. Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine. J Acquir Immune Defic Syndr 7: 1141-1148.
    • (1994) J Acquir Immune Defic Syndr , vol.7 , pp. 1141-1148
    • Alder, J.1    Hutch, T.2    Meulbroek, J.A.3    Clement, J.C.4
  • 19
    • 0030902084 scopus 로고    scopus 로고
    • Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis
    • Khan AA, Slifer T, Araujo FG, Polzer RJ, Remington JS. 1997. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrob Agents Chemother 41: 893-897.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 893-897
    • Khan, A.A.1    Slifer, T.2    Araujo, F.G.3    Polzer, R.J.4    Remington, J.S.5
  • 21
    • 0018758843 scopus 로고
    • The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo
    • Grossman PL, Remington JS. 1979. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg 28: 445-455.
    • (1979) Am J Trop Med Hyg , vol.28 , pp. 445-455
    • Grossman, P.L.1    Remington, J.S.2
  • 22
    • 0025159211 scopus 로고
    • Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase
    • Allegra CJ, Boarman D, Kovacs JA, Morrison P, Beaver J, Chabner BA, Masur H. 1990. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest 85: 371-379. http://dx.doi.org/10.1172/JCI114448.
    • (1990) J Clin Invest , vol.85 , pp. 371-379
    • Allegra, C.J.1    Boarman, D.2    Kovacs, J.A.3    Morrison, P.4    Beaver, J.5    Chabner, B.A.6    Masur, H.7
  • 24
    • 0028148943 scopus 로고
    • Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii
    • Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC. 1994. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother 38: 1803-1807. http://dx.doi.org/10.1128/AAC.38.8.1803.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 1803-1807
    • Chang, H.R.1    Arsenijevic, D.2    Comte, R.3    Polak, A.4    Then, R.L.5    Pechère, J.C.6
  • 26
    • 0032827171 scopus 로고    scopus 로고
    • Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models
    • Dumas JL, Pizzolato G, Pechère JC. 1999. Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents 13: 35-39. http://dx.doi.org/10.1016/S0924-8579(99)00073-4.
    • (1999) Int J Antimicrob Agents , vol.13 , pp. 35-39
    • Dumas, J.L.1    Pizzolato, G.2    Pechère, J.C.3
  • 28
    • 0000812934 scopus 로고
    • Effect of clindamycin on acute and chronic toxoplasmosis in mice
    • Araujo FG, Remington JS. 1974. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother 5: 647-651. http://dx.doi.org/10.1128/AAC.5.6.647.
    • (1974) Antimicrob Agents Chemother , vol.5 , pp. 647-651
    • Araujo, F.G.1    Remington, J.S.2
  • 29
    • 0029044369 scopus 로고
    • In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii
    • Fichera ME, Bhopale MK, Roos DS. 1995. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 39: 1530-1537. http://dx.doi.org/10.1128/AAC.39.7.1530.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1530-1537
    • Fichera, M.E.1    Bhopale, M.K.2    Roos, D.S.3
  • 30
    • 0036227773 scopus 로고    scopus 로고
    • An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii
    • Camps M, Arrizabalaga G, Boothroyd J. 2002. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol Microbiol 43: 1309-1318. http://dx.doi.org/10.1046/j.1365 -2958.2002.02825.x.
    • (2002) Mol Microbiol , vol.43 , pp. 1309-1318
    • Camps, M.1    Arrizabalaga, G.2    Boothroyd, J.3
  • 31
    • 0023155159 scopus 로고
    • Potent in vitro and in vivo antitoxoplasma activity of the lipidsoluble antifolate trimetrexate
    • Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. 1987. Potent in vitro and in vivo antitoxoplasma activity of the lipidsoluble antifolate trimetrexate. J Clin Invest 79: 478-482. http://dx.doi .org/10.1172/JCI112837.
    • (1987) J Clin Invest , vol.79 , pp. 478-482
    • Allegra, C.J.1    Kovacs, J.A.2    Drake, J.C.3    Swan, J.C.4    Chabner, B.A.5    Masur, H.6
  • 32
    • 0030028511 scopus 로고    scopus 로고
    • Rifapentine is active in vitro and in vivo against Toxoplasma gondii
    • Araujo FG, Khan AA, Remington JS. 1996. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother 40: 1335-1337.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 1335-1337
    • Araujo, F.G.1    Khan, A.A.2    Remington, J.S.3
  • 33
    • 0034732665 scopus 로고    scopus 로고
    • Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance
    • McFadden DC, Tomavo S, Berry EA, Boothroyd JC. 2000. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 108: 1-12. http://dx.doi.org/10.1016/S0166-6851(00)00184-5.
    • (2000) Mol Biochem Parasitol , vol.108 , pp. 1-12
    • McFadden, D.C.1    Tomavo, S.2    Berry, E.A.3    Boothroyd, J.C.4
  • 34
    • 0025318581 scopus 로고
    • In vitro and in vivo effects of doxycycline on Toxoplasma gondii
    • Chang HR, Comte R, Pechère JC. 1990. In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother 34: 775-780. http://dx.doi.org/10.1128/AAC.34.5.775.
    • (1990) Antimicrob Agents Chemother , vol.34 , pp. 775-780
    • Chang, H.R.1    Comte, R.2    Pechère, J.C.3
  • 35
    • 33748707031 scopus 로고    scopus 로고
    • Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum
    • Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. 2006. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 50: 3124-3131. http://dx.doi.org/10.1128/AAC.00394-06.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 3124-3131
    • Dahl, E.L.1    Shock, J.L.2    Shenai, B.R.3    Gut, J.4    DeRisi, J.L.5    Rosenthal, P.J.6
  • 36
    • 0022469629 scopus 로고
    • Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice
    • Chan J, Luft BJ. 1986. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrob Agents Chemother 30: 323-324. http://dx.doi.org/10.1128/AAC.30.2.323.
    • (1986) Antimicrob Agents Chemother , vol.30 , pp. 323-324
    • Chan, J.1    Luft, B.J.2
  • 37
    • 0023546829 scopus 로고
    • In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice
    • Luft BJ. 1987. In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice. Eur J Clin Microbiol 6: 479-481. http://dx .doi.org/10.1007/BF02013115.
    • (1987) Eur J Clin Microbiol , vol.6 , pp. 479-481
    • Luft, B.J.1
  • 38
    • 0025917362 scopus 로고
    • In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii
    • Araujo FG, Shepard RM, Remington JS. 1991. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 10: 519-524. http://dx.doi.org/10.1007/BF01963942.
    • (1991) Eur J Clin Microbiol Infect Dis , vol.10 , pp. 519-524
    • Araujo, F.G.1    Shepard, R.M.2    Remington, J.S.3
  • 39
    • 0025818451 scopus 로고
    • Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay
    • Chamberland S, Kirst HA, Current WL. 1991. Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Antimicrob Agents Chemother 35: 903-909. http://dx .doi.org/10.1128/AAC.35.5.903.
    • (1991) Antimicrob Agents Chemother , vol.35 , pp. 903-909
    • Chamberland, S.1    Kirst, H.A.2    Current, W.L.3
  • 41
    • 0030862066 scopus 로고    scopus 로고
    • The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection
    • Araujo FG, Khan AA, Slifer TL, Bryskier A, Remington JS. 1997. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother 41: 2137-2140.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 2137-2140
    • Araujo, F.G.1    Khan, A.A.2    Slifer, T.L.3    Bryskier, A.4    Remington, J.S.5
  • 42
    • 84938497069 scopus 로고    scopus 로고
    • Could miltefosine be used as a therapy for toxoplasmosis?
    • Eissa MM, Barakat AMA, Amer EI, Younis LK. 2015. Could miltefosine be used as a therapy for toxoplasmosis? Exp Parasitol 157: 12-22. http://dx.doi.org/10.1016/j.exppara.2015.06.005.
    • (2015) Exp Parasitol , vol.157 , pp. 12-22
    • Eissa, M.M.1    Barakat, A.M.A.2    Amer, E.I.3    Younis, L.K.4
  • 45
    • 84921033998 scopus 로고    scopus 로고
    • Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis
    • El-Zawawy LA, El-Said D, Mossallam SF, Ramadan HS, Younis SS. 2015. Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis. Exp Parasitol 149: 54-64. http://dx.doi.org/10.1016/j.exppara.2014.12.007.
    • (2015) Exp Parasitol , vol.149 , pp. 54-64
    • El-Zawawy, L.A.1    El-Said, D.2    Mossallam, S.F.3    Ramadan, H.S.4    Younis, S.S.5
  • 46
    • 84908689732 scopus 로고    scopus 로고
    • Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii
    • El-Zawawy LA, El-Said D, Mossallam SF, Ramadan HS, Younis SS. 2015. Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii. Acta Trop 141: 103-111. http://dx.doi.org/10.1016/j .actatropica.2014.09.020.
    • (2015) Acta Trop , vol.141 , pp. 103-111
    • El-Zawawy, L.A.1    El-Said, D.2    Mossallam, S.F.3    Ramadan, H.S.4    Younis, S.S.5
  • 49
    • 70349320504 scopus 로고    scopus 로고
    • Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model
    • Dunay IR, Chan WC, Haynes RK, Sibley LD. 2009. Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model. Antimicrob Agents Chemother 53: 4450-4456. http://dx.doi.org/10.1128/AAC.00502-09.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 4450-4456
    • Dunay, I.R.1    Chan, W.C.2    Haynes, R.K.3    Sibley, L.D.4
  • 50
    • 0034030445 scopus 로고    scopus 로고
    • Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii
    • Sarciron ME, Saccharin C, Petavy AF, Peyron F. 2000. Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii.AmJ Trop Med Hyg 62: 73-76.
    • (2000) AmJ Trop Med Hyg , vol.62 , pp. 73-76
    • Sarciron, M.E.1    Saccharin, C.2    Petavy, A.F.3    Peyron, F.4
  • 51
    • 33845268199 scopus 로고    scopus 로고
    • In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin
    • Jones-Brando L, D'Angelo J, Posner GH, Yolken R. 2006. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob Agents Chemother 50: 4206-4208. http://dx.doi.org/10 .1128/AAC.00793-06.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 4206-4208
    • Jones-Brando, L.1    D'Angelo, J.2    Posner, G.H.3    Yolken, R.4
  • 52
    • 77952065567 scopus 로고    scopus 로고
    • Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii
    • Hencken CP, Jones-Brando L, Bordón C, Stohler R, Mott BT, Yolken R, Posner GH, Woodard LE. 2010. Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. J Med Chem 53: 3594-3601. http://dx.doi.org/10.1021/jm901857d.
    • (2010) J Med Chem , vol.53 , pp. 3594-3601
    • Hencken, C.P.1    Jones-Brando, L.2    Bordón, C.3    Stohler, R.4    Mott, B.T.5    Yolken, R.6    Posner, G.H.7    Woodard, L.E.8
  • 53
    • 0022517822 scopus 로고
    • Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis
    • Luft BJ. 1986. Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis. J Infect Dis 154: 692-694. http://dx.doi .org/10.1093/infdis/154.4.692.
    • (1986) J Infect Dis , vol.154 , pp. 692-694
    • Luft, B.J.1
  • 54
    • 0023914919 scopus 로고
    • Toxoplasma gondii: In vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide
    • Pfefferkorn ER, Eckel ME, McAdams E. 1988. Toxoplasma gondii: In vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide. Exp Parasitol 65: 282-289. http://dx.doi.org/10.1016/0014-4894(88)90133-6.
    • (1988) Exp Parasitol , vol.65 , pp. 282-289
    • Pfefferkorn, E.R.1    Eckel, M.E.2    McAdams, E.3
  • 55
    • 0027360238 scopus 로고
    • Toxoplasma gondii: Susceptibility and development of resistance to anticoccidial drugs in vitro
    • Ricketts AP, Pfefferkorn ER. 1993. Toxoplasma gondii: Susceptibility and development of resistance to anticoccidial drugs in vitro. Antimicrob Agents Chemother 37: 2358-2363. http://dx.doi.org/10.1128/AAC .37.11.2358.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 2358-2363
    • Ricketts, A.P.1    Pfefferkorn, E.R.2
  • 56
    • 0028270498 scopus 로고
    • Activity of diclazuril against Toxoplasma gondii in cultured cells and mice
    • Lindsay DS, Blagburn BL. 1994. Activity of diclazuril against Toxoplasma gondii in cultured cells and mice. Am J Vet Res 55: 530-533.
    • (1994) Am J Vet Res , vol.55 , pp. 530-533
    • Lindsay, D.S.1    Blagburn, B.L.2
  • 57
    • 0028951645 scopus 로고
    • Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine
    • Lindsay DS, Rippey NS, Blagburn BL. 1995. Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine. J Parasitol 81: 315-318. http://dx.doi.org/10.2307/3283944.
    • (1995) J Parasitol , vol.81 , pp. 315-318
    • Lindsay, D.S.1    Rippey, N.S.2    Blagburn, B.L.3
  • 58
    • 3142708505 scopus 로고    scopus 로고
    • Efficacy of ponazuril in vitro and in preventing and treating Toxoplasma gondii infections in mice
    • Mitchell SM, Zajac AM, Davis WL, Lindsay DS. 2004. Efficacy of ponazuril in vitro and in preventing and treating Toxoplasma gondii infections in mice. J Parasitol 90: 639-642. http://dx.doi.org/10.1645/GE -250R.
    • (2004) J Parasitol , vol.90 , pp. 639-642
    • Mitchell, S.M.1    Zajac, A.M.2    Davis, W.L.3    Lindsay, D.S.4
  • 59
    • 84873703023 scopus 로고    scopus 로고
    • In-vivo efficacy of toltrazuril on experimentally induced Toxoplasma gondii tissue cysts in lambs: A novel strategy for prevention of human exposure to meatborne toxoplasmosis
    • Kul O, Yildiz K, Ocal N, Freyre A, Deniz A, Karahan S, Atmaca HT, Gokpinar S, Dincel GC, Uzunaliog?lu T, Terzi OS. 2013. In-vivo efficacy of toltrazuril on experimentally induced Toxoplasma gondii tissue cysts in lambs: A novel strategy for prevention of human exposure to meatborne toxoplasmosis. Res Vet Sci 94: 269-276. http://dx.doi.org/10.1016/j.rvsc.2012.08.001.
    • (2013) Res Vet Sci , vol.94 , pp. 269-276
    • Kul, O.1    Yildiz, K.2    Ocal, N.3    Freyre, A.4    Deniz, A.5    Karahan, S.6    Atmaca, H.T.7    Gokpinar, S.8    Dincel, G.C.9    Uzunalioglu, T.10    Terzi, O.S.11
  • 60
    • 84930190688 scopus 로고    scopus 로고
    • Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis
    • Jain V, Yogavel M, Oshima Y, Kikuchi H, Touquet B, Hakimi M-A, Sharma A. 2015. Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. Structure 23: 819-829. http://dx.doi.org/10.1016/j.str .2015.02.011.
    • (2015) Structure , vol.23 , pp. 819-829
    • Jain, V.1    Yogavel, M.2    Oshima, Y.3    Kikuchi, H.4    Touquet, B.5    Hakimi, M.-A.6    Sharma, A.7
  • 61
    • 84887224619 scopus 로고    scopus 로고
    • Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice
    • Payne AJ, Neal LM, Knoll LJ. 2013. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res 112: 3859-3863. http://dx.doi.org/10.1007/s00436 -013-3574-1.
    • (2013) Parasitol Res , vol.112 , pp. 3859-3863
    • Payne, A.J.1    Neal, L.M.2    Knoll, L.J.3
  • 63
    • 0028293350 scopus 로고
    • Rifabutin is active in murine models of toxoplasmosis
    • Araujo FG, Slifer T, Remington JS. 1994. Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother 38: 570-575. http://dx.doi.org/10.1128/AAC.38.3.570.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 570-575
    • Araujo, F.G.1    Slifer, T.2    Remington, J.S.3
  • 64
    • 0029821109 scopus 로고    scopus 로고
    • In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii
    • Romand S, Della Bruna C, Farinotti R, Derouin F. 1996. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Antimicrob Agents Chemother 40: 2015-2020.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 2015-2020
    • Romand, S.1    Della Bruna, C.2    Farinotti, R.3    Derouin, F.4
  • 66
    • 0035160778 scopus 로고    scopus 로고
    • Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii
    • Khan AA, Slifer TR, Araujo FG, Remington JS. 2001. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother 45: 48-51. http://dx.doi.org/10.1128/AAC.45.1.48-51.2001.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 48-51
    • Khan, A.A.1    Slifer, T.R.2    Araujo, F.G.3    Remington, J.S.4
  • 67
    • 84860666014 scopus 로고    scopus 로고
    • Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models
    • Barbosa BF, Gomes AO, Ferro EAV, Napolitano DR, Mineo JR, Silva NM. 2012. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models. Vet Parasitol 187: 44-52. http://dx.doi.org/10.1016/j.vetpar.2011.12.039.
    • (2012) Vet Parasitol , vol.187 , pp. 44-52
    • Barbosa, B.F.1    Gomes, A.O.2    Ferro, E.A.V.3    Napolitano, D.R.4    Mineo, J.R.5    Silva, N.M.6
  • 68
    • 42449130430 scopus 로고    scopus 로고
    • Itraconazole affects Toxoplasma gondii endodyogeny
    • Martins-Duarte EDS, de Souza W, Vommaro RC. 2008. Itraconazole affects Toxoplasma gondii endodyogeny. FEMS Microbiol Lett 282: 290-298. http://dx.doi.org/10.1111/j.1574-6968.2008.01130.x.
    • (2008) FEMS Microbiol Lett , vol.282 , pp. 290-298
    • Martins-Duarte, E.D.S.1    De Souza, W.2    Vommaro, R.C.3
  • 69
    • 76849113239 scopus 로고    scopus 로고
    • Toxoplasma gondii: Fluconazole and itraconazole activity against toxoplasmosis in a murine model
    • Martins-Duarte ES, Lemgruber L, de Souza W, Vommaro RC. 2010. Toxoplasma gondii: Fluconazole and itraconazole activity against toxoplasmosis in a murine model. Exp Parasitol 124: 466-469. http://dx.doi .org/10.1016/j.exppara.2009.12.011.
    • (2010) Exp Parasitol , vol.124 , pp. 466-469
    • Martins-Duarte, E.S.1    Lemgruber, L.2    De Souza, W.3    Vommaro, R.C.4
  • 70
    • 84872463692 scopus 로고    scopus 로고
    • Toxoplasma gondii: The effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model
    • Martins-Duarte ÉS, de Souza W, Vommaro RC. 2013. Toxoplasma gondii: The effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. Exp Parasitol 133: 294-299. http://dx.doi.org/10.1016/j.exppara.2012.12.011.
    • (2013) Exp Parasitol , vol.133 , pp. 294-299
    • Martins-Duarte, E.S.1    De Souza, W.2    Vommaro, R.C.3
  • 72
    • 0031738886 scopus 로고    scopus 로고
    • Alterations of Toxoplasma gondii induced by 2=,3=-dideoxyinosine in vitro
    • Sarciron ME, Lawton P, Petavy AF, Peyron F. 1998. Alterations of Toxoplasma gondii induced by 2=,3=-dideoxyinosine in vitro. J Parasitol 84: 1055-1059. http://dx.doi.org/10.2307/3284647.
    • (1998) J Parasitol , vol.84 , pp. 1055-1059
    • Sarciron, M.E.1    Lawton, P.2    Petavy, A.F.3    Peyron, F.4
  • 73
    • 0034150015 scopus 로고    scopus 로고
    • Toxoplasma encephalitis: Influence of the vehicle on the efficacy of different doses of 2=,3=- dideoxyinosine in mice
    • Gherardi A, Sarciron ME, Peyron F. 2000. Toxoplasma encephalitis: Influence of the vehicle on the efficacy of different doses of 2=,3=- dideoxyinosine in mice. Parasite 7: 39-42. http://dx.doi.org/10.1051/parasite/2000071039.
    • (2000) Parasite , vol.7 , pp. 39-42
    • Gherardi, A.1    Sarciron, M.E.2    Peyron, F.3
  • 74
    • 84872821556 scopus 로고    scopus 로고
    • Antiretroviral activity of protease inhibitors against Toxoplasma gondii
    • Monzote L, Rodríguez M, Alfonso Y, Cox R. 2013. Antiretroviral activity of protease inhibitors against Toxoplasma gondii. Rev Inst Med Trop Sao Paulo 55: 65-67. http://dx.doi.org/10.1590/S0036 -46652013000100012.
    • (2013) Rev Inst Med Trop Sao Paulo , vol.55 , pp. 65-67
    • Monzote, L.1    Rodríguez, M.2    Alfonso, Y.3    Cox, R.4
  • 75
    • 0023829936 scopus 로고
    • In vitro assessment of antimicrobial agents against Toxoplasma gondii
    • Harris C, Salgo MP, Tanowitz HB, Wittner M. 1988. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis 157: 14-22. http://dx.doi.org/10.1093/infdis/157.1.14.
    • (1988) J Infect Dis , vol.157 , pp. 14-22
    • Harris, C.1    Salgo, M.P.2    Tanowitz, H.B.3    Wittner, M.4
  • 76
    • 84907149529 scopus 로고    scopus 로고
    • Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells
    • Yang Z, Ahn H-J, Nam H-W. 2014. Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells. Korean J Parasitol 52: 439-441. http://dx.doi.org/10.3347/kjp.2014.52.4.439.
    • (2014) Korean J Parasitol , vol.52 , pp. 439-441
    • Yang, Z.1    Ahn, H.-J.2    Nam, H.-W.3
  • 77
    • 0029792379 scopus 로고    scopus 로고
    • Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis
    • Sumyuen MH, Garin YJ, Derouin F. 1996. Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis. Parasitol Res 82: 681-686. http://dx.doi.org/10.1007/s004360050185.
    • (1996) Parasitol Res , vol.82 , pp. 681-686
    • Sumyuen, M.H.1    Garin, Y.J.2    Derouin, F.3
  • 78
    • 0022504494 scopus 로고
    • The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro
    • McCabe RE, Luft BJ, Remington JS. 1986. The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro. Transplantation 41: 611-615. http://dx.doi.org/10.1097/00007890-198605000-00012.
    • (1986) Transplantation , vol.41 , pp. 611-615
    • McCabe, R.E.1    Luft, B.J.2    Remington, J.S.3
  • 79
    • 0032868347 scopus 로고    scopus 로고
    • Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase
    • Darling JA, Sullivan WJ, Carter D, Ullman B, Roos DS. 1999. Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase. Mol Biochem Parasitol 103: 15-23. http://dx .doi.org/10.1016/S0166-6851(99)00109-7.
    • (1999) Mol Biochem Parasitol , vol.103 , pp. 15-23
    • Darling, J.A.1    Sullivan, W.J.2    Carter, D.3    Ullman, B.4    Roos, D.S.5
  • 80
    • 84905510190 scopus 로고    scopus 로고
    • Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis
    • Andrade RM, Chaparro JD, Capparelli E, Reed SL. 2014. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl Trop Dis 8: E2973. http://dx.doi.org/10.1371/journal.pntd.0002973.
    • (2014) PLoS Negl Trop Dis , vol.8 , pp. e2973
    • Andrade, R.M.1    Chaparro, J.D.2    Capparelli, E.3    Reed, S.L.4
  • 81
    • 79953829695 scopus 로고    scopus 로고
    • Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures
    • Goodwin DG, Strobl JS, Lindsay DS. 2011. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol 97: 148-151. http://dx.doi.org/10.1645/GE-2536.1.
    • (2011) J Parasitol , vol.97 , pp. 148-151
    • Goodwin, D.G.1    Strobl, J.S.2    Lindsay, D.S.3
  • 82
    • 0037787955 scopus 로고    scopus 로고
    • Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii
    • Jones-Brando L, Torrey EF, Yolken R. 2003. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 62: 237-244. http://dx.doi.org/10 .1016/S0920-9964(02)00357-2.
    • (2003) Schizophr Res , vol.62 , pp. 237-244
    • Jones-Brando, L.1    Torrey, E.F.2    Yolken, R.3
  • 84
    • 84946414991 scopus 로고    scopus 로고
    • Posting date. Current therapy of acquired ocular toxoplasmosis: A review
    • 30 July
    • Lima GSC, Saraiva PGC, Saraiva FP. 30 July 2015, posting date. Current therapy of acquired ocular toxoplasmosis: A review. J Ocul Pharmacol Ther http://dx.doi.org/10.1089/jop.2015.0059.
    • (2015) J Ocul Pharmacol Ther
    • Lima, G.S.C.1    Saraiva, P.G.C.2    Saraiva, F.P.3
  • 87
    • 30144444390 scopus 로고    scopus 로고
    • Merck & Co. 10th ed. Merck & Co., Inc., Whitehouse Station, NJ
    • Merck & Co. 2010. The Merck veterinary manual, 10th ed. Merck & Co., Inc., Whitehouse Station, NJ.
    • (2010) The Merck Veterinary Manual
  • 90
    • 33845680984 scopus 로고    scopus 로고
    • In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections
    • Ozdek SC, Miller D, Flynn PM, Flynn HW. 2006. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm 14: 347-351. http://dx.doi.org/10.1080/09273940600976953.
    • (2006) Ocul Immunol Inflamm , vol.14 , pp. 347-351
    • Ozdek, S.C.1    Miller, D.2    Flynn, P.M.3    Flynn, H.W.4
  • 91
    • 78049397500 scopus 로고    scopus 로고
    • Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections
    • Nau R, Sörgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23: 858-883. http://dx .doi.org/10.1128/CMR.00007-10.
    • (2010) Clin Microbiol Rev , vol.23 , pp. 858-883
    • Nau, R.1    Sörgel, F.2    Eiffert, H.3
  • 92
    • 0014865202 scopus 로고
    • The effect of rifampin on Toxoplasma gondii
    • Remington JS, Yagura T, Robinson WS. 1970. The effect of rifampin on Toxoplasma gondii. Proc Soc Exp Biol Med 135: 167-172. http://dx.doi .org/10.3181/00379727-135-35011.
    • (1970) Proc Soc Exp Biol Med , vol.135 , pp. 167-172
    • Remington, J.S.1    Yagura, T.2    Robinson, W.S.3
  • 93
    • 1642335814 scopus 로고    scopus 로고
    • History of the development of azole derivatives
    • Maertens JA. 2004. History of the development of azole derivatives. Clin Microbiol Infect 10(Suppl 1): S1-S10.
    • (2004) Clin Microbiol Infect , vol.10 , pp. S1-S10
    • Maertens, J.A.1
  • 94
    • 4544283160 scopus 로고    scopus 로고
    • Prevalence of toxoplasma encephalitis in AIDS patients treated with didanosine hospitalised in a French infectious service
    • Sarciron M-E, Ghérardi A, Delorme C, Peyramond D, Pétavy A-F. 2004. Prevalence of toxoplasma encephalitis in AIDS patients treated with didanosine hospitalised in a French infectious service. Curr HIV Res 2: 301-307. http://dx.doi.org/10.2174/1570162043351101.
    • (2004) Curr HIV Res , vol.2 , pp. 301-307
    • Sarciron, M.-E.1    Ghérardi, A.2    Delorme, C.3    Peyramond, D.4    Pétavy, A.-F.5
  • 96
    • 42549123787 scopus 로고    scopus 로고
    • Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system
    • Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. 2008. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7: 12. http://dx .doi.org/10.1186/jbiol69.
    • (2008) J Biol , vol.7 , pp. 12
    • Han, R.1    Yang, Y.M.2    Dietrich, J.3    Luebke, A.4    Mayer-Pröschel, M.5    Noble, M.6
  • 97
    • 77956332686 scopus 로고    scopus 로고
    • Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses
    • Peixoto L, Chen F, Harb OS, Davis PH, Beiting DP, Brownback CS, Ouloguem D, Roos DS. 2010. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe 8: 208-218. http://dx.doi.org/10.1016/j.chom.2010.07.004.
    • (2010) Cell Host Microbe , vol.8 , pp. 208-218
    • Peixoto, L.1    Chen, F.2    Harb, O.S.3    Davis, P.H.4    Beiting, D.P.5    Brownback, C.S.6    Ouloguem, D.7    Roos, D.S.8
  • 98
    • 65049089761 scopus 로고    scopus 로고
    • C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation
    • De Mattia E, Toffoli G. 2009. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 45: 1333-1351. http://dx.doi.org/10.1016/j .ejca.2008.12.004.
    • (2009) Eur J Cancer , vol.45 , pp. 1333-1351
    • De Mattia, E.1    Toffoli, G.2
  • 99
    • 0029875638 scopus 로고    scopus 로고
    • Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations
    • Piper JR, Johnson CA, Krauth CA, Carter RL, Hosmer CA, Queener SF, Borotz SE, Pfefferkorn ER. 1996. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. J Med Chem 39: 1271-1280.
    • (1996) J Med Chem , vol.39 , pp. 1271-1280
    • Piper, J.R.1    Johnson, C.A.2    Krauth, C.A.3    Carter, R.L.4    Hosmer, C.A.5    Queener, S.F.6    Borotz, S.E.7    Pfefferkorn, E.R.8
  • 100
    • 0030765061 scopus 로고    scopus 로고
    • Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology
    • Silverman JA, Hayes ML, Luft BJ, Joiner KA. 1997. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob Agents Chemother 41: 1859-1866.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1859-1866
    • Silverman, J.A.1    Hayes, M.L.2    Luft, B.J.3    Joiner, K.A.4
  • 102
    • 34548032814 scopus 로고    scopus 로고
    • Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis
    • Torrey EF, Bartko JJ, Lun Z-R, Yolken RH. 2007. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr Bull 33: 729-736. http://dx.doi.org/10.1093/schbul/sbl050.
    • (2007) Schizophr Bull , vol.33 , pp. 729-736
    • Torrey, E.F.1    Bartko, J.J.2    Lun, Z.-R.3    Yolken, R.H.4
  • 104
    • 84874692147 scopus 로고    scopus 로고
    • Development of Toxoplasma gondii vaccine: A global challenge
    • Verma R, Khanna P. 2013. Development of Toxoplasma gondii vaccine: A global challenge. Hum Vaccin Immunother 9: 291-293. http://dx.doi .org/10.4161/hv.22474.
    • (2013) Hum Vaccin Immunother , vol.9 , pp. 291-293
    • Verma, R.1    Khanna, P.2
  • 105
    • 84919708683 scopus 로고    scopus 로고
    • Recent advances in Toxoplasma gondii immunotherapeutics
    • Lim SS-Y, Othman RY. 2014. Recent advances in Toxoplasma gondii immunotherapeutics. Korean J Parasitol 52: 581-593. http://dx.doi.org/10.3347/kjp.2014.52.6.581.
    • (2014) Korean J Parasitol , vol.52 , pp. 581-593
    • Lim, S.S.-Y.1    Othman, R.Y.2
  • 106
    • 84961678088 scopus 로고    scopus 로고
    • Posting date. In vivo efficacy of drugs acting on Toxoplasma gondii combined with immunomodulators
    • 10 July
    • Köksal ZS, Yanik K, Bilgin K, MutluYilmaz E, Hokelek M. 10 July 2015, posting date. In vivo efficacy of drugs acting on Toxoplasma gondii combined with immunomodulators. Jpn J Infect Dis http://dx.doi.org/10.7883/yoken.JJID.2015.023.
    • (2015) Jpn J Infect Dis
    • Köksal, Z.S.1    Yanik, K.2    Bilgin, K.3    MutluYilmaz, E.4    Hokelek, M.5

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.